I’m thrilled to be attending the upcoming 2013 BIO International Convention that is coming to Chicago April 22-25. The educational sessions, networking, business forum, and exhibits are coming together to form the strongest Convention to date. Of course, I may be biased being a Chicago native but I can’t think of a better venue and backdrop for the rapidly evolving biotechnology industry. The City of Chicago is known for its architects and novel designs, a reputation dating back to the days of Daniel Burnham and enhanced in the years following the Great Chicago Fire of 1871. Chicago’s own entrepreneurial community is a growing ecosystem rising from an infrastructure as stable as the foundation upon which the city was built. Like the architects and planners that created a new Chicago, today’s local and international entrepreneurs are turning visions into innovation, designing new business models as much as they are developing new technologies.
The 2013 Convention will have so many offerings which can be leveraged by all participants in the industry from all over the globe. Whether you are meeting up with investors or prospective partners, learning new material from the program sessions or simply meeting colleagues to touch base and re-kindle old business relationships, the Convention in Chicago offers a melting pot of unparalleled opportunities.
Global, pharmaceutical, biotechnology and ag-bio companies will be in full force at the 2013 BIO International Convention. The event is a comprehensive program and can be overwhelming if one does not plan ahead.
I plan to utilize the “myBIO” personal event planner to schedule my attendance in several tracks, including finance, tech transfer, biotech patenting, and business development. The BIO One-on-One Partnering System will allow me to schedule personal meetings with top pharma and biotech Business Development executives.
One of the first sessions I plan to add to my schedule will be Monday morning’s special program, Biotech Primer: Top 10 Biotech Advances, for a full summary of the most exciting advances in biotech in the past year.
With so much attention focused on universities partnering with pharmaceutical companies on early-stage technologies, I am looking forward to attending one of the conference Super Sessions, Innovative Innovation: New Partners, New Partnerships, so that I can learn how biotech companies are accelerating the time and reducing the cost between concept and cure. I am intrigued by Tuesday’s session titled, adVENTURES in Academic Partnering, a discussion about ways that allow relevant research to scale the ivy walls and make it to pharma’s pipelines.
Chicago is home to many venture capital and life science investment firms, and Tuesday morning’s breakout session entitled, Money Ball – Winning Venture Strategies, should be quite useful for these firms as well as any company looking to raise capital in 2013. Attendees will hear a panel discussion about the new ways that traditional venture capitalists are de-risking investments. As Managing Director of Flavin Ventures, LLC, www.flavinventures.com a venture creation and management VC firm, this finance session will provide useful information that we can share with our portfolio companies.
I will also be interested to learn why and how charitable organizations invest in biotech companies at Monday’s session, Venture Philanthropy: For-Profit Biotechs can Benefit from Non-Profit Investments.
Lastly, I will tune in to the patent sessions to stay abreast of new changes in the law and how that will affect our companies and the industry in general. These sessions include The Unitary Patent: what impact on the biotech sector and your business? and Developments in the Law of Patentable Subject Matter: Myriad, Mayo, and Beyond.
In the same way Chicago gave the world its early skyscrapers based on innovative architecture and design, coupled with hard work and patience, Chicago’s biotech industry is advancing a blueprint for creating cutting-edge biomedical products, business models and financing structures. We are thrilled to host the international biotechnology community at the 2013 BIO International Convention and showcase our progress in advancing the industry.
John L. Flavin is the Managing Director of Flavin Ventures, LLC, Executive Director of Chicago Innovation Mentors and BIO 2013 program committee co-chair.